{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:26:37Z","timestamp":1792639597169,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#23\/2020"],"award-info":[{"award-number":["FFC#23\/2020"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#7\/2022"],"award-info":[{"award-number":["FFC#7\/2022"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.tube.2022.102301","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T11:55:53Z","timestamp":1672314953000},"page":"102301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Preclinical murine models to study lung infection with Mycobacterium abscessus complex"],"prefix":"10.1016","volume":"138","author":[{"given":"Francesca","family":"Nicola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M.","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9159-1632","authenticated-orcid":false,"given":"Nicola I.","family":"Lor\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2022.102301_bib1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tube.2022.102301_bib2","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2022.102301_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.tube.2022.102301_bib4","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1128\/IAI.67.9.4700-4707.1999","article-title":"Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection","volume":"67","author":"Byrd","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.tube.2022.102301_bib5","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1099\/mic.0.28625-0","article-title":"Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype","volume":"152","author":"Howard","year":"2006","journal-title":"Microbiology"},{"key":"10.1016\/j.tube.2022.102301_bib6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/mmi.12387","article-title":"Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus","volume":"90","author":"Pawlik","year":"2013","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.tube.2022.102301_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2164-8-114","article-title":"Genomics of glycopeptidolipid biosynthesis in Mycobacterium abscessus and M. chelonae","volume":"8","author":"Ripoll","year":"2007","journal-title":"BMC Genom"},{"key":"10.1016\/j.tube.2022.102301_bib8","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.vaccine.2015.03.030","article-title":"Bacterial phospholipases C as vaccine candidate antigens against cystic fibrosis respiratory pathogens: the Mycobacterium abscessus model","volume":"33","author":"Le Moigne","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2022.102301_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1189\/jlb.1007696","article-title":"Animal model of Mycobacterium abscessus lung infection","volume":"83","author":"Ordway","year":"2008","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.tube.2022.102301_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-60452-1","article-title":"A mouse model of pulmonary Mycobacteroides abscessus infection","volume":"10","author":"Maggioncalda","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.tube.2022.102301_bib11","author":"Story-Roller"},{"key":"10.1016\/j.tube.2022.102301_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102268","article-title":"Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice","volume":"137","author":"Sriram","year":"2022","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2022.102301_bib14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jac\/dkt451","article-title":"GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus","volume":"69","author":"De Groote","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01477","article-title":"Nucleotide-binding oligomerization domain 2 contributes to limiting growth of Mycobacterium abscessus in the lung of mice by regulating cytokines and nitric oxide production","volume":"8","author":"Lee","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.tube.2022.102301_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01943-19","article-title":"Rifabutin is active against Mycobacterium abscessus in mice","volume":"64","author":"Dick","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib17","article-title":"Epetraborole is active against Mycobacterium abscessus","volume":"65","author":"Ganapathy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02420-20","article-title":"A leucyl-tRNA synthetase inhibitor with broad-spectrum anti-mycobacterial activity","volume":"65","author":"Ganapathy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009965","article-title":"Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline","volume":"17","author":"Sullivan","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tube.2022.102301_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02752-16","article-title":"Activity of LCB01-0371, a novel oxazolidinone, against Mycobacterium abscessus","volume":"61","author":"Kim","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738070","article-title":"Type I interferons are involved in the intracellular growth control of Mycobacterium abscessus by mediating NOD2-induced production of nitric oxide in macrophages","volume":"12","author":"Ahn","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.tube.2022.102301_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/cells9030648","article-title":"The peroxisome proliferator-activated receptor \u03b1- agonist gemfibrozil promotes defense against Mycobacterium abscessus infections","volume":"9","author":"Kim","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.tube.2022.102301_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117657","article-title":"Mycobacterium abscessus morphotype comparison in a murine model","volume":"10","author":"Caverly","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2022.102301_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21186590","article-title":"A new model of chronic Mycobacterium abscessus lung infection in immunocompetent mice","volume":"21","author":"Riva","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tube.2022.102301_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01541-2022","article-title":"The aminoglycoside-modifying enzyme Eis2 represents a new potential in vivo target for reducing antimicrobial drug resistance in Mycobacterium abscessus complex","volume":"60","author":"Lor\u00e8","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2022.102301_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02546-21","article-title":"Combined host- and pathogen-directed therapy for the control of Mycobacterium abscessus infection","volume":"10","author":"Poerio","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.tube.2022.102301_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00114-20","article-title":"Efficacy of bedaquiline, alone or in combination with imipenem, against Mycobacterium abscessus in C3HeB\/FeJ mice","volume":"64","author":"Le Moigne","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","article-title":"Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections","volume":"18","author":"Banaschewski","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.tube.2022.102301_bib29","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1128\/AAC.00142-14","article-title":"In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system","volume":"58","author":"Bernut","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/infdis\/jit614","article-title":"In vivo evaluation of antibiotic activity against Mycobacterium abscessus","volume":"209","author":"Lerat","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2022.102301_bib31","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1128\/AAC.00459-15","article-title":"Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models","volume":"59","author":"Obreg\u00f3n-Henao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02245-18","article-title":"Indole-2-Carboxamides are active against Mycobacterium abscessus in a mouse model of acute infection","volume":"63","author":"Pandya","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj3860","article-title":"Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in Mycobacterium abscessus","volume":"14","author":"Belardinelli","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tube.2022.102301_bib34","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1128\/IAI.00014-07","article-title":"Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL\/6 mice","volume":"75","author":"Rottman","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.tube.2022.102301_bib35","article-title":"British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"4","author":"Haworth","year":"2017","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.tube.2022.102301_bib36","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.tube.2022.102301_bib37","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: a new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria","volume":"15","author":"Van Ingen","year":"2012","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.tube.2022.102301_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00827-19","article-title":"Bedaquiline eliminates bactericidal activity of \u03b2-lactams against Mycobacterium abscessus","volume":"63","author":"Lindman","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/1469-0691.12405","article-title":"In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex","volume":"20","author":"Lavollay","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.tube.2022.102301_bib41","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","article-title":"Discovery of a potent and specific M. tuberculosis leucyl-tRNA synthetase inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)","volume":"60","author":"Li","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2022.102301_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00240-19","article-title":"First-Time-in-Human study and prediction of early bactericidal activity for GSK3036656, a potent leucyl-tRNA synthetase inhibitor for tuberculosis treatment","volume":"63","author":"Tenero","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102301_bib43","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.bmc.2017.05.015","article-title":"Design, synthesis and evaluation of indole-2-carboxamides with Pan anti-mycobacterial activity graphical abstract HHS public access","volume":"149","author":"Franz","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.tube.2022.102301_bib44","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1021\/jm4012774","article-title":"Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents","volume":"56","author":"Kondreddi","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2022.102301_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3907","article-title":"Indoleamides are active against drug-resistant Mycobacterium tuberculosis","volume":"4","author":"Lun","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.tube.2022.102301_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007355","article-title":"Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis","volume":"5","author":"Rao","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tube.2022.102301_bib47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijid.2017.10.013","article-title":"Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis","volume":"65","author":"Lee","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tube.2022.102301_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1165\/rcmb.2009-0276TR","article-title":"Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease","volume":"43","author":"Chan","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.tube.2022.102301_bib49","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1462-5822.2010.01565.x","article-title":"Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants","volume":"13","author":"Roux","year":"2011","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.tube.2022.102301_bib50","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/j.1462-5822.2008.01151.x","article-title":"Mycobacterium abscessus activates the macrophage innate immune response via a physical and functional interaction between TLR2 and dectin-1","volume":"10","author":"Shin","year":"2008","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.tube.2022.102301_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.00432","article-title":"A TLR2-activating fraction from Mycobacterium abscessus rough variant demonstrates vaccine and diagnostic potential","volume":"10","author":"Le Moigne","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.tube.2022.102301_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02888","article-title":"Mycobacterium abscessus-bronchial epithelial cells cross-talk through type I interferon signaling","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.tube.2022.102301_bib53","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41564-021-00963-3","article-title":"Dissemination of Mycobacterium abscessus via global transmission networks","volume":"6","author":"Ruis","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.tube.2022.102301_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb8699","article-title":"Stepwise pathogenic evolution of Mycobacterium abscessus","volume":"372","author":"Bryant","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.tube.2022.102301_bib55","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3390\/antibiotics11101322","article-title":"Alternatives to antibiotics against Mycobacterium abscessus","volume":"11","author":"Broncano-Lavado","year":"2022","journal-title":"Antibiotica"},{"key":"10.1016\/j.tube.2022.102301_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pathogens9080641","article-title":"Preclinical models of nontuberculous mycobacteria infection for early drug discovery and vaccine research","volume":"9","author":"Rampacci","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.tube.2022.102301_bib57","doi-asserted-by":"crossref","unstructured":"Meir M, Barkan D. Molecular Sciences Alternative and Experimental Therapies of Mycobacterium abscessus Infections n.d. https:\/\/doi.org\/10.3390\/ijms21186793.","DOI":"10.3390\/ijms21186793"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147297922200138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147297922200138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:48:06Z","timestamp":1761468486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147297922200138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":57,"alternative-id":["S147297922200138X"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2022.102301","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical murine models to study lung infection with Mycobacterium abscessus complex","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2022.102301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102301"}}